vs
科睿唯安（CLVT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是科睿唯安的1.1倍（$622.0M vs $585.5M），Royalty Pharma plc净利率更高（34.4% vs -6.9%，领先41.3%），Royalty Pharma plc同比增速更快（4.8% vs -1.4%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CLVT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$585.5M
营收增速更快
RPRX
高出6.2%
-1.4%
净利率更高
RPRX
高出41.3%
-6.9%
两年增速更快
RPRX
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $622.0M |
| 净利润 | $-40.2M | $214.2M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 5.2% | 62.4% |
| 净利率 | -6.9% | 34.4% |
| 营收同比 | -1.4% | 4.8% |
| 净利润同比 | 61.3% | 2.9% |
| 每股收益（稀释后） | $-0.06 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTRPRX
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $622.0M | ||
| Q3 25 | $623.1M | $609.3M | ||
| Q2 25 | $621.4M | $578.7M | ||
| Q1 25 | $593.7M | $568.2M | ||
| Q4 24 | $663.0M | $593.6M | ||
| Q3 24 | $622.2M | $564.7M | ||
| Q2 24 | $650.3M | $537.3M |
净利润CLVTRPRX
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $214.2M | ||
| Q3 25 | $-28.3M | $288.2M | ||
| Q2 25 | $-72.0M | $30.2M | ||
| Q1 25 | $-103.9M | $238.3M | ||
| Q4 24 | $-191.8M | $208.2M | ||
| Q3 24 | $-65.6M | $544.0M | ||
| Q2 24 | $-304.3M | $102.0M |
毛利率CLVTRPRX
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — |
营业利润率CLVTRPRX
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 62.4% | ||
| Q3 25 | 7.1% | 70.1% | ||
| Q2 25 | 1.1% | 36.3% | ||
| Q1 25 | -3.5% | 94.0% | ||
| Q4 24 | -9.4% | 60.9% | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | -36.9% | 50.2% |
净利率CLVTRPRX
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 34.4% | ||
| Q3 25 | -4.5% | 47.3% | ||
| Q2 25 | -11.6% | 5.2% | ||
| Q1 25 | -17.5% | 41.9% | ||
| Q4 24 | -28.9% | 35.1% | ||
| Q3 24 | -10.5% | 96.3% | ||
| Q2 24 | -46.8% | 19.0% |
每股收益（稀释后）CLVTRPRX
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.49 | ||
| Q3 25 | $-0.04 | $0.67 | ||
| Q2 25 | $-0.11 | $0.07 | ||
| Q1 25 | $-0.15 | $0.55 | ||
| Q4 24 | $-0.27 | $0.46 | ||
| Q3 24 | $-0.09 | $1.21 | ||
| Q2 24 | $-0.46 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $4.3B | $9.0B |
| 股东权益账面价值 | $4.8B | $9.7B |
| 总资产 | $10.9B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.89× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CLVTRPRX
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $618.7M | ||
| Q3 25 | $318.7M | $938.9M | ||
| Q2 25 | $362.6M | $631.9M | ||
| Q1 25 | $354.0M | $1.1B | ||
| Q4 24 | $295.2M | $929.0M | ||
| Q3 24 | $388.5M | $950.1M | ||
| Q2 24 | $376.4M | $1.8B |
总债务CLVTRPRX
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $9.0B | ||
| Q3 25 | $4.4B | $8.9B | ||
| Q2 25 | $4.5B | $8.0B | ||
| Q1 25 | $4.5B | $7.6B | ||
| Q4 24 | $4.5B | $7.6B | ||
| Q3 24 | $4.6B | $7.6B | ||
| Q2 24 | $4.6B | $7.6B |
股东权益CLVTRPRX
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $9.7B | ||
| Q3 25 | $4.9B | $9.6B | ||
| Q2 25 | $5.0B | $9.5B | ||
| Q1 25 | $5.0B | $9.8B | ||
| Q4 24 | $5.1B | $10.3B | ||
| Q3 24 | $5.5B | $10.3B | ||
| Q2 24 | $5.6B | $9.8B |
总资产CLVTRPRX
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $19.6B | ||
| Q3 25 | $11.2B | $19.3B | ||
| Q2 25 | $11.4B | $18.3B | ||
| Q1 25 | $11.5B | $17.6B | ||
| Q4 24 | $11.5B | $18.2B | ||
| Q3 24 | $12.0B | $18.0B | ||
| Q2 24 | $12.1B | $17.7B |
负债/权益比CLVTRPRX
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | 0.92× | ||
| Q3 25 | 0.90× | 0.93× | ||
| Q2 25 | 0.90× | 0.84× | ||
| Q1 25 | 0.90× | 0.78× | ||
| Q4 24 | 0.88× | 0.74× | ||
| Q3 24 | 0.84× | 0.74× | ||
| Q2 24 | 0.83× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | — |
| 自由现金流率自由现金流/营收 | 13.5% | — |
| 资本支出强度资本支出/营收 | 9.5% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $333.9M | — |
8季度趋势，按日历期对齐
经营现金流CLVTRPRX
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $827.1M | ||
| Q3 25 | $181.1M | $702.6M | ||
| Q2 25 | $116.3M | $364.0M | ||
| Q1 25 | $171.2M | $596.1M | ||
| Q4 24 | $141.3M | $742.5M | ||
| Q3 24 | $202.9M | $703.6M | ||
| Q2 24 | $126.2M | $658.2M |
自由现金流CLVTRPRX
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $50.3M | — | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $126.3M | — | ||
| Q2 24 | $60.3M | — |
自由现金流率CLVTRPRX
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 9.3% | — |
资本支出强度CLVTRPRX
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 12.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 10.1% | — |
现金转化率CLVTRPRX
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
